4369 — Tri Chemical Laboratories Balance Sheet
0.000.00%
- ¥100bn
- ¥98bn
- ¥19bn
- 88
- 31
- 64
- 70
Annual balance sheet for Tri Chemical Laboratories, fiscal year end - January 31st, JPY millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1,699 | 8,034 | 11,138 | 10,497 | 9,439 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,902 | 3,896 | 4,562 | 4,035 | 5,220 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 7,585 | 14,386 | 18,923 | 19,009 | 21,456 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7,880 | 8,014 | 8,373 | 9,269 | 10,936 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 19,868 | 28,289 | 32,116 | 31,865 | 36,945 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,290 | 3,465 | 3,676 | 2,554 | 4,182 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 7,266 | 6,969 | 6,239 | 4,295 | 5,357 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 12,601 | 21,320 | 25,876 | 27,570 | 31,588 |
| Total Liabilities & Shareholders' Equity | 19,868 | 28,289 | 32,116 | 31,865 | 36,945 |
| Total Common Shares Outstanding |